Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
BiogenIdec
>
Latest News - ADU won't be approved
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6471582"]<a href="https://www.barrons.com/articles/biogen-bet-on-alzheimers-drug-faces-poor-odds-says-ubs-51603920772" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://www.barrons.com/articles/biogen-bet-on-alzheimers-drug-faces-poor-odds-says-ubs-51603920772" rel="nofollow">Biogen Bet on Alzheimer’s Drug Faces Poor Odds, Says UBS</a></p><p><br /></p><p><i>UBS now giving it a 5% likelihood of approval: A survey of regulatory experts by UBS concludes that FDA approval is unlikely, however, after two clinical trials of the drug reached two different results. Biogen declared one of them positive, only after initially declaring that trial negative. The positive revision relied on analysis that imputes values for data that is actually missing, says Bristow. He concludes that aducanumab’s chances for approval are just 5%.</i></p><p><br /></p><p>Net/net - The studies failed. Biogen (aka Michel) hoping for a moonshot to save his job as he has invested billions in these ALZ programs while deferring to use that capital in real BD / M&A. Think about all of the companies that Biogen could of purchased with commercial and/or commercial-ready assets to stave-off the generic erosion of the MS business (e.g. Avexis, Alexion, Sarepta, etc.).</p><p><br /></p><p>Oh...and don't forget the billions in stock buy-backs to keep the share price high so that the executives can line their pockets as they sell off their shares.[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6471582"][URL="https://www.barrons.com/articles/biogen-bet-on-alzheimers-drug-faces-poor-odds-says-ubs-51603920772"]Biogen Bet on Alzheimer’s Drug Faces Poor Odds, Says UBS[/URL] [I]UBS now giving it a 5% likelihood of approval: A survey of regulatory experts by UBS concludes that FDA approval is unlikely, however, after two clinical trials of the drug reached two different results. Biogen declared one of them positive, only after initially declaring that trial negative. The positive revision relied on analysis that imputes values for data that is actually missing, says Bristow. He concludes that aducanumab’s chances for approval are just 5%.[/I] Net/net - The studies failed. Biogen (aka Michel) hoping for a moonshot to save his job as he has invested billions in these ALZ programs while deferring to use that capital in real BD / M&A. Think about all of the companies that Biogen could of purchased with commercial and/or commercial-ready assets to stave-off the generic erosion of the MS business (e.g. Avexis, Alexion, Sarepta, etc.). Oh...and don't forget the billions in stock buy-backs to keep the share price high so that the executives can line their pockets as they sell off their shares.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
BiogenIdec
>
Latest News - ADU won't be approved
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
BiogenIdec
>
Latest News - ADU won't be approved
>